The court would rule in sue's favor because courts seldom inquire into the adequacy of consideration.
In contracts, <em>consideration </em>just means the <em>exchange of things of value</em>. There has to be an exchange of things of value for there to be an enforceable contract, and in this case a watch was exchanged for money. It is rare for courts to rule on how much consideration is expected because people are generally free to set their own prices and not sell if the price is too low. That is not for a court to decide (in most cases).
Answer:
reduce its cash account by $1875.
reduce its cash account by $410.
Explanation:
As for the information provided,
When we tally the cash balance with that of bank balance,
Outstanding checks which were already deducted in cash book will be added as yet outstanding and payment not made.
= + 3,025
Deposits in transit were already added in cash book, although yet not added to bank balance, thus deducted
= - 4,900
= +3,025 - 4,900 = - $1875
This means cash will be reduced by $1,875
Further NSF check is already added in cash but not yet added in bank = - $310
Further bank has deducted charges but in cash book not recorded thus it will be deducted now = - $100
= -$310 - $100 = - $410
Answer:
c. is an important feature of the increase in income inequality
Explanation:
Income inequality measures how unevenly income is distributed throughout a population.
A price regulation that put a price cap on the apartment rents a landlord is permitted to charge leads to underproduction. A monopoly leads to underproduction. The answer is both under productions in the monopoly leads and apartment rent leads.
I can help with question two, but not question three.
The answer to question two is that biotech companies are part of the global industry from day one. Because capital is global, diseases know no borders, people are mobile, and you can get science anywhere in the world, there is an immediate competition with all other bioscience companies in the world.
In other words, when you start a biotech company in the US, you are immediately competing with biotech companies in Japan, the UK, etc. because you're all competing for the same capital, the same consumers, the same pharmacies, etc.
My best guess for question three is just that regulations are always important for global businesses (or really any business in general) as they protect both the businesses, the employees, and the consumers. In the case of biotech businesses, they protect people from false advertising of the benefits of products for example.
Hope this helps!